Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

Semglee (insulin glargine )

Indications: Diabetes mellitus, Type 1 & 2

Call For Patient Input: October 16, 2018

Patient Input Closed: December 4, 2018

Fulphila (pegfilgrastim)

Indications: Febrile neutropenia in non-myeloid malignancies

Call For Patient Input: October 16, 2018

Patient Input Closed: December 4, 2018

Cimzia (certolizumab pegol )

Indications: Psoriasis, moderate to severe plaque

Call For Patient Input: October 15, 2018

Patient Input Closed: December 3, 2018

Cresemba (isavuconazole )

Indications: Treatment of invasive aspergillosis and mucormycosis.

Call For Patient Input: October 4, 2018

Patient Input Closed: November 23, 2018

TBC (filgrastim)

Indications: Prevention or treatment of neutropenia in various indications

Call For Patient Input: October 3, 2018

Patient Input Closed: November 22, 2018

Botox (onabotulinumtoxinA)

Indications: migraine, chronic

Call For Patient Input: September 26, 2018

Patient Input Closed: November 15, 2018

TBC (risankizumab)

Indications: Psoriasis, moderate to severe plaque

Call For Patient Input: September 19, 2018

Patient Input Closed: November 8, 2018

TBC (doravirine lamuvidine tenofovir disoproxil fumarate)

Indications: HIV-1

Call For Patient Input: September 14, 2018

Patient Input Closed: November 5, 2018

TBC (doravirine)

Indications: HIV-1

Call For Patient Input: September 14, 2018

Patient Input Closed: November 5, 2018